Häfner D, Germann P G, Hauschke D
Pulm Pharmacol. 1994 Oct;7(5):319-32. doi: 10.1006/pulp.1994.1038.
Repetitive lung lavage of adult rats leads to lung injury similar to ARDS resulting in poor gas exchange, protein leakage and infiltration of polymorphonuclear neutrophils (PMN) into the alveolar spaces (J Appl Physiol 1983; 55: 131-138). In a previous dose response comparison we have demonstrated that poor gas exchange could be improved by lung surfactant factor (LSF) instillation soon after lavage. Since Surfacten (Tokyo Tanabe Co. Ltd., Tokyo, Japan) was described in vitro to inhibit PMN activity, we compared this preparation with a Recombinant LSF preparation (Byk Gulden, Konstanz, Germany; phospholipids plus human identical surfactant protein C) at doses of 25, 50 and 100 mg/kg body weight. Their efficacy was compared with an untreated control group with respect to improving gas exchange, inhibition of hyaline membrane formation and inhibition of the inflammatory response after multiple lavage. Tracheotomized rats were pressure-controlled ventilated (Siemens Servo Ventilator 900C, Sweden) with 100% oxygen at a respiratory rate of 30 breaths/min, inspiration:expiration ratio of 1:2, peak inspiratory pressure (PIP) of 28 cmH2O at positive end-expiratory pressure (PEEP) of 8 cmH2O. Two hours after LSF administration PEEP was reduced from 8 to 6 cmH2O (first PEEP-reduction), from 6 to 3 (second reduction) and from 3 to 0 cmH2O (third reduction) and finally raised to 8 cmH2O. Results for the averaged partial arterial oxygen pressure [PaO2 (mmHg)] of the 2 h period [PaO2(5'-120')] and for the PaO2 during the second PEEP reduction [PaO2(PEEP23/3] were calculated. Both LSF preparations caused a dose-dependent increase of the PaO2 (5'-120') and the PaO2(PEEP23/3). Similarly, the formation of hyaline membranes was inhibited by both LSF preparations in a dose-dependent manner. Inhibition of the inflammatory response (infiltration of PMN) was not effected by either of the LSF preparations at any dose level. The described variations in ventilator settings are useful to evaluate the deflation stability and re-expansion potential of different LSF preparations. The reported results give evidence that prevention of atelectasis by LSF treatment improves gas exchange and inhibits formation of hyaline membranes, leading to the conclusion that LSF treatment may be a promising therapy in ARDS patients.
对成年大鼠进行反复肺灌洗会导致类似于急性呼吸窘迫综合征(ARDS)的肺损伤,从而引起气体交换不良、蛋白质渗漏以及多形核中性粒细胞(PMN)浸润到肺泡腔中(《应用生理学杂志》1983年;55:131 - 138)。在之前的剂量反应比较中,我们已经证明灌洗后立即注入肺表面活性物质因子(LSF)可以改善气体交换不良的情况。由于在体外研究中发现Surfacten(日本东京田边制药有限公司)能抑制PMN活性,我们将这种制剂与重组LSF制剂(德国康斯坦茨的Byk Gulden公司生产;磷脂加与人相同的表面活性蛋白C)以25、50和100mg/kg体重的剂量进行了比较。在多次灌洗后,就改善气体交换、抑制透明膜形成以及抑制炎症反应方面,将它们的疗效与未治疗的对照组进行了比较。对行气管切开术的大鼠使用西门子Servo Ventilator 900C型呼吸机(瑞典)进行压力控制通气,吸入100%氧气,呼吸频率为30次/分钟,吸气:呼气比为1:2,在呼气末正压(PEEP)为8cmH₂O时的吸气峰压(PIP)为28cmH₂O。在注入LSF后两小时,将PEEP从8cmH₂O降至6cmH₂O(第一次降低PEEP),从6cmH₂O降至3cmH₂O(第二次降低),从3cmH₂O降至0cmH₂O(第三次降低),最后再升至8cmH₂O。计算了2小时时间段内的平均动脉血氧分压[PaO₂(mmHg)][PaO₂(5' - 120')]以及第二次降低PEEP期间的PaO₂[PaO₂(PEEP23/3)]。两种LSF制剂均导致PaO₂(5' - 120')和PaO₂(PEEP23/3)呈剂量依赖性增加。同样,两种LSF制剂均以剂量依赖性方式抑制透明膜的形成。在任何剂量水平下,两种LSF制剂均未对炎症反应(PMN浸润)产生抑制作用。所描述的呼吸机设置变化有助于评估不同LSF制剂的放气稳定性和再扩张潜力。所报告的结果表明,通过LSF治疗预防肺不张可改善气体交换并抑制透明膜的形成,从而得出结论:LSF治疗可能是ARDS患者一种有前景的治疗方法。